Ischaemic Heart Disease vs Acute Coronary Syndrome: Complete 2026 Doctor’s Guide

By Dr. Sagar Rajkuwar, ENT Specialist, Nashik, Maharashtra, India
🌐 www.entspecialistinnashik.com

Short answer: Ischaemic heart disease (IHD) is the broad, mostly chronic umbrella term for any heart disease caused by inadequate blood flow to the myocardium. Acute coronary syndrome (ACS) is the acute, emergency subset of IHD — it includes unstable angina, non-ST-elevation myocardial infarction (NSTEMI), and ST-elevation myocardial infarction (STEMI). In simple terms: IHD is the lifelong disease; ACS is the sudden, life-threatening event within that disease. If you are confused by ischaemic heart disease vs acute coronary syndrome, this 2026 ENT-authored guide — aligned with WHO, CDC, NHS, Fourth Universal Definition of MI 2018, AHA/ACC 2023, and ESC 2023 ACS Guidelines — walks you through every difference.

Table of Contents

1. Introduction
2. Defining the Terms
3. IHD = Chronic Umbrella; ACS = Acute Event
4. Pathophysiology Compared
5. Clinical Spectrum Compared
6. Symptoms Compared
7. ECG & Biomarker Differences
8. Investigations Compared
9. Treatment Compared
10. Prognosis & Complications
11. Comparison Table
12. Prevention — Same Risk Factors
13. External Video Resource
14. FAQs
15. Conclusion
16. References

1. Introduction

Patients and students often mix up these terms when reading reports or discharge letters. Understanding ischaemic heart disease vs acute coronary syndrome is critical because the two carry very different urgency, treatment pathways and prognoses.

2. Defining the Terms

2.1 Ischaemic heart disease (IHD)

Any heart disease caused by inadequate oxygenated blood supply to the myocardium. Includes:

• Stable angina
• Silent ischaemia
• Chronic coronary syndromes (CCS)
• Ischaemic cardiomyopathy, heart failure
• Microvascular angina, variant angina
• All forms of acute coronary syndrome

2.2 Acute coronary syndrome (ACS)

An acute presentation of IHD caused by sudden reduction or complete loss of coronary blood flow — usually from plaque rupture, plaque erosion or acute thrombus. ACS covers:

• Unstable angina (UA)
• Non-ST-elevation MI (NSTEMI)
• ST-elevation MI (STEMI)

3. IHD = Chronic Umbrella; ACS = Acute Event

Think of IHD as the long-term disease label, and ACS as what happens when IHD “flares” dramatically. A patient with IHD may be stable for years before experiencing an ACS event. Conversely, ACS is sometimes the very first clinical manifestation of previously silent IHD.

This is the heart of ischaemic heart disease vs acute coronary syndrome.

4. Pathophysiology Compared

4.1 IHD (chronic forms)

• Fixed atherosclerotic plaque causing >50–70% stenosis
• Supply failure only on exertion
• Microvascular dysfunction
• Vasospasm (variant angina)

4.2 ACS

• Vulnerable plaque with a thin fibrous cap
• Rupture → platelet aggregation → thrombus
• Partial occlusion → UA/NSTEMI
• Complete occlusion → STEMI
• Microembolisation of distal coronary bed

5. Clinical Spectrum Compared

5.1 IHD spectrum

• Subclinical atherosclerosis
• Stable (effort) angina — CCS Grade I–IV
• Silent ischaemia
• Ischaemic cardiomyopathy & HFrEF
• Arrhythmias due to chronic ischaemia
• All ACS presentations

5.2 ACS spectrum

• Unstable angina — new/resting/crescendo angina without troponin rise
• NSTEMI — ischaemic chest pain + raised troponin without ST-elevation
• STEMI — ST-elevation + raised troponin
• Peri-arrest ACS, cardiogenic shock, sudden cardiac death

6. Symptoms Compared

6.1 IHD (stable)

• Predictable exertional chest discomfort
• Relieved by rest or sublingual nitroglycerin
• Episodes last 2–15 minutes
• Reproducible with similar exertion

6.2 ACS

• Chest pain at rest or minimal exertion
• Lasts >20 minutes, not relieved by rest/nitrates
• Severe cold sweating (diaphoresis), nausea, vomiting
• Breathlessness, palpitations, syncope
• Sense of impending doom

7. ECG & Biomarker Differences

7.1 ECG in IHD

• Resting ECG may be normal
• Stress-ECG: ≥1 mm horizontal/downsloping ST-depression during exercise
• Old Q-waves from previous MI
• LBBB, LVH strain

7.2 ECG in ACS

• ST-elevation (STEMI)
• ST-depression ≥0.5 mm in two contiguous leads (NSTEMI/UA)
• T-wave inversion, hyperacute T-waves
• Wellens, De Winter patterns
• New LBBB (STEMI equivalent)

7.3 Biomarkers

• Stable IHD: troponin not elevated
• UA: troponin normal
• NSTEMI/STEMI: raised high-sensitivity troponin I/T
• BNP/NT-proBNP: elevated in heart failure due to chronic IHD or acute LV dysfunction

8. Investigations Compared

8.1 For stable IHD

• Resting ECG
• Lipid profile, HbA1c, Lp(a)
• Echocardiography
• Stress ECG, stress echo, SPECT MPI, PET
• CT coronary angiography — first-line in ESC 2024
• Invasive coronary angiography if high risk
• FFR, iFR during angiography

8.2 For ACS

• Immediate 12-lead ECG within 10 min
• High-sensitivity troponin at 0 and 1–3 hours
• Bedside echocardiography
• Urgent coronary angiography for STEMI (<90 min) or high-risk NSTEMI (<24 h)
• Chest X-ray, basic metabolic panel

9. Treatment Compared

9.1 Stable IHD

• Lifestyle: Mediterranean/DASH diet, exercise, no tobacco
• Anti-anginals: beta-blockers, calcium-channel blockers, long-acting nitrates, ranolazine, trimetazidine, ivabradine
• Antiplatelet (aspirin), high-intensity statin
• ACE-I/ARB if indicated
• Revascularisation (PCI or CABG) for refractory or high-risk anatomy

9.2 ACS

• Immediate: oxygen if SpO₂ <90%, aspirin 325 mg chewable, nitroglycerin, morphine if severe pain, dual antiplatelet therapy (aspirin + ticagrelor/prasugrel), anticoagulation (heparin/bivalirudin), high-intensity statin
• STEMI: primary PCI within 90 min, or fibrinolysis if PCI not possible within 120 min
• NSTEMI: early invasive strategy within 24 h for high-risk patients
• Long-term: dual antiplatelet 6–12 months, high-intensity statin, beta-blocker, ACE-I, SGLT2 inhibitor, cardiac rehabilitation

10. Prognosis & Complications

• Stable IHD: good with optimal medical therapy; mortality 1–3% per year
• UA/NSTEMI: 30-day mortality ~5%
• STEMI: in-hospital mortality 5–10% in developed systems; higher where PCI access is limited
• Both can lead to heart failure, arrhythmia, cardiogenic shock, sudden death

11. Comparison Table

12. Prevention — Same Risk Factors

Whether you have IHD or an ACS event, the modifiable risk factors are the same:

• Mediterranean/DASH diet
• 150+ minutes/week exercise
• No tobacco
• BP <130/80 mmHg
• LDL at target with statins ± ezetimibe ± PCSK9 inhibitors
• HbA1c <7% if diabetic; SGLT2 inhibitors / GLP-1 RAs
• Healthy weight & waist
• Sleep 7–9 hours; treat OSA
• Daily stress management
• Regular screening (lipids, glucose, Lp(a) once, CAC in intermediate risk)

13. External Video Resource

Watch a focused explainer on ischaemic heart disease vs acute coronary syndrome:

YouTube: IHD vs ACS Explained – AHA / BHF / Osmosis

14. FAQs

Q1. Is ACS a type of IHD?

Yes. ACS is the acute emergency subset of IHD.

Q2. Can IHD exist without ever causing ACS?

Yes. Many patients have stable IHD for decades without an acute event.

Q3. Can ACS be the first sign of IHD?

Yes — up to 25% of first heart attacks occur in previously undiagnosed patients.

Q4. Is unstable angina an ACS or IHD?

Both — it is an acute presentation (ACS) within the chronic disease process (IHD).

Q5. Which is more urgent?

ACS is a true emergency. Stable IHD is managed in clinic.

Q6. Does ACS always need PCI?

STEMI needs urgent reperfusion. NSTEMI/UA risk-stratified — most high-risk patients receive early invasive management.

Q7. Can ACS occur without CAD?

Yes — MINOCA (MI with non-obstructive coronaries) accounts for 5–10% of MI, from microvascular, vasospasm, SCAD or Takotsubo mechanisms.

Q8. Can I prevent progression from IHD to ACS?

Yes — strict risk-factor control, statins, antiplatelets as indicated, and regular follow-up substantially reduce ACS risk.

15. Conclusion

So, ischaemic heart disease vs acute coronary syndrome: IHD is the chronic umbrella; ACS is the acute, emergency subset. Stable IHD is managed in the clinic with lifestyle, antianginals and statins; ACS demands immediate hospital care, dual antiplatelet therapy, high-intensity statins and often emergency revascularisation. The same modifiable risk factors drive both — and tight control at every stage prevents progression to the next.

16. References

1. Vrints C, et al. 2024 ESC Guidelines on Chronic Coronary Syndromes.
2. Byrne RA, et al. 2023 ESC Guidelines for the Management of Acute Coronary Syndromes.
3. Thygesen K, et al. Fourth Universal Definition of MI, 2018 (updated 2023).
4. Lawton JS, et al. 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularisation.
5. WHO Cardiovascular Diseases Fact Sheet 2024.
6. NHS UK ACS overview 2024.
7. CDC Heart Attack facts 2024.

📞 ENT Consultation & Surgery

Dr. Sagar Rajkuwar (MS-ENT)
Prabha ENT Clinic, Ambad, Nashik
📱 7387590194 | 9892596635
🌐 www.entspecialistinnashik.com

Medical Disclaimer

Medical Disclaimer: This article is for educational purposes only and does not replace professional medical advice, diagnosis, or treatment. Audiogram results should be interpreted by a qualified audiologist or ENT specialist. If you have sudden hearing loss, severe dizziness, ear discharge, or other concerning symptoms, seek medical evaluation promptly. Suspected ACS is a medical emergency — call ambulance immediately.